



New A Innovation
新意康

13th March 2012

Dr Nikolazus Kriz
Veterinary Medicines and Inspections Unit
European Medicines Agency
7 Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom

Subject: Withdrawal of Oxapex 65mg/ml solution for infusion for dogs: EMEA/V/C/002342

Dear Sir,

I would like to inform you that, at this point of time, New A Innovation (NL) Limited B.V. has taken the decision to withdraw the application for Marketing Authorisation of **Oxapex 65mg/ml solution for infusion for dogs**, which was intended to be used for the treatment of acute hemorrhagic shock by increasing plasma hemoglobin to reverse oxygen deficit and improve the clinical signs of hypoxia.

At this time, this withdrawal is based on the following reasons:

- The company business strategy with internal on-going Research & Development.
- The CVMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s)/target species, if applicable.

I agree for this letter to be published on the EMEA website.

Yours faithfully,

Peter Pang
General Manager, Scientific Affairs
New A Innovation (NL) Limited B.V.

新意康医药科技有限公司 New A Innovation Limited

总部 Head Office: 香港九龙湾宏开道八号英士商业中心十七楼 17/F Chevalier Commercial Centre, 8 Wang Hoi Road, Kowloon Bay, Kowloon, Hong Kong
生产基地 Manufacturing Plant: 香港新界沙田大埔公路十二哩生物科技路二号生物科技研究院三楼 3/F Hong Kong Institute of Biotechnology, 2 Biotechnology Avenue, 12 Miles, Tai Po Road, Shatin, New Ter

www.newainnovation.com